Traditionally, two divergent approaches are used to explain the mechanism of action of psychotropic drugs. The dominant ''Disease-centred" view emphasises the biochemical imbalance caused by 'illnesses'. In contrast the ''Drug-centred" view emphasises the psychoactive properties of these drugs and their ability to induce an 'altered-state' of mind. In this article we propose a new paradigm for classifying the therapeutic uses of psychotropic drugs based on the relation between their psychoactive effects and symptoms of indicated mental illness; as well as their clinical responses e.g. emerging tolerance, paradoxical initial worsening and being recommended for long/ short term use. Based on this premise, therapeutic uses of psychotropic drugs can be placed on a continuum between two distinguishable modes. We define these modes as ''Psycho-antagonistic" and ''Psycho-agonistic". 105 therapeutic uses of 85 psychotropic drugs are placed on this continuum; 74% on the Psycho-agnostic spectrum and 25% on the Psycho-antagonistic side. Hypnotic agents used for insomnia are clear examples of Psycho-antagonistic mode of use. Citalopram for treatment of Panic disorder is a clear example of using a drug in Psycho-agonistic mode. Only the therapeutic use of Lithium for bipolar affective disorder could not be allocated to any mode and considered as borderline. The paradigm highlights the possibility of initial worsening in majority of therapeutic uses of psychotropic drugs and importance of using lower doses. Further studies and clinical trials are needed to explore the full extent of the clinical implications of this paradigm in psychiatry and perhaps in other branches of medicine.
Introduction
Psychotropic drugs are used successfully to treat mentally unwell patients. Alteration in brain neuro-chemistry has been the best evidenced and most accepted explanation of the effects of such drugs since the 1950-60 s [1] . Indeed most of the recent advances in our pharmacological toolkit are due to scientific advances and clinical trials based on this 'Disease-centred' model. This model has replaced an older, more clinically oriented model of how psychotropic drugs may work. This latter approach is based on the concept of the psychoactive properties of psychotropic medication and the possibility of inducing an altered mental state to explain the mechanism of action of same [2] . For example, Deniker in 1960 suggested that neuroleptic drugs work by inducing a neurological syndrome consisting of physical restriction and mental symptoms such as cognitive slowing, apathy, and emotional flattening, which resembled Parkinson's disease [3] .
This point of view has recently led to the development of a 'Drug-centred' model by Dr. Joanna Moncrieff [4] to explain the mechanism of action of psychotropic drugs. In this approach the effect of psychotropic drugs are considered to be similar to the effects of psychoactive substances that: ''induce complex, varied, often unpredictable physical and mental states that patients typically experience as global, rather than distinct therapeutic effects and side effects" and that their ''therapeutic effects are the consequence of being in an altered mental state" [4] . Whilst the model is clearly at odds with current scientific thinking, there may be some benefit in exploring how psychological alterations produced by psychotropic drugs interact with the symptoms experienced by patients with clearly defined mental illness.
In addition, Moncrieff's model suggests that any such approach needs to consider the psychological changes due to psychotropic drugs on healthy subjects -otherwise the effect of the drug may be altered or masked by the symptoms of the illness. For example the sedative properties of a drug might be completely different when prescribed to an aroused in contrast to a drowsy patient. In reality however, it is rare to find such studies on healthy subjects in the published medical literature [4] .
Within the spirit of an exploratory approach to the interaction between the psychoactive properties of a psychotropic drug and the symptoms of mental illness that it is licensed to treat we propose an alternative option. This is to use the published summaries of the toxicity and side effect profiles of each psychotropic drug as a proxy measure of their psychoactive effect in a healthy subject. This information also presents the unintended but still psychoactive properties of psychotropic drugs. In clinical practice the interface between the therapeutic properties and side effects of a drug becomes blurred on some situations. Using the reported side effect of Mirtazapine of 'increasing appetite' as a desirable property in treating an anorexic patient with depression is a good example of how reported side effects can have therapeutic uses [5] . Therefore, in this article we shall use the terms 'Side-effect' and 'Psychoactive properties/ effects' synonymously and interchangeably.
Hypothesis
Based on this premise, we propose that therapeutic uses of psychotropic drugs can be placed on a continuum between two distinguishable modes. Their locus along the continuum is based on the relationship between their psychoactive effects and the symptoms of the illness for which they are prescribed in addition to their therapeutic responses. We define these modes as ''Psycho-antagonistic" and ''Psycho-agonistic" and their defining characteristics are outlined below ( Table 1) .
We propose that all psychotropic drugs could be placed along this continuum as illustrated ( Fig. 1 ) by using the number of the criteria they meet. It is important to highlight here that the terms Psycho-antagonistic and Psycho-agonistic are descriptive only and do not imply any disease-targeted mechanism or receptor oriented theory.
Evaluation of hypothesis
The first and second authors (FS & MG) conducted a review of the medical literature on the reported side effect profile and clinical responses of psychotropic medication in relation to the symptoms of those mental illnesses they are prescribed to treat (clinical indication). They independently reviewed each drug in the British National Formulary's (BNF) classes 4.1-4.4 and 4.11 [6] along with their specific clinical indications, from August 2009 to Nov 2015. Any discrepancy was discussed in order to arrive at a consensus. In the BNF the clinical indications are listed as an illness/mental disorder (e.g. Schizophrenia) or a symptom (e.g. insomnia). In the case of mental illness/disorder, the symptom profile was taken from the definition of the illness/disorder as specified in the International Classification of Diseases, 10th edition (ICD-10) [7] . In the Table 1 Modes of therapeutic uses.
Mode
Definition of therapeutic use
Psycho-antagonistic 1. The drug's psychoactive effect is opposite to the symptoms of its indicated mental illness/disorder 2. It is recommended for short term use 3. Tolerance is likely to develop with use over a few weeks Psycho-agonistic 1. The drug's psychoactive effect mimics the symptoms of its indicated mental illness/disorder 2. It is recommended for longer term use. 'Symptom reduction' occurs gradually over time without the development of tolerance 3. There is a possibility of an initial worsening of some symptoms How psychotropic drugs are used; an explanatory paradigm S25 next step the side effect profile of each drug as described in the BNF and clinical responses were noted. For each drug, the side-effect profile was cross-matched to the indication profile listed for that drug.
For example drowsiness is one of the side effects (psychoactive effect) of Zopiclone used as a hypnotic, which is opposite to insomnia [6] . In addition, Zopiclone is recommended for short-term treatment of insomnia as one develops tolerance in few weeks after initial therapeutic response. Therefore the use of Zopiclone for treatment of insomnia is strongly in Psycho-antagonistic mode. On the other hand, Citalopram is licensed for the treatment of Panic disorder. The BNF has identified ''palpitation, tachycardia, impaired concentration, paraesthesia, dry mouth, nervousness, anxiety, insomnia, tremor, dizziness..." as potential side effects (psychoactive effects) of Citalopram with less sedative effect comparing to other anti-anxiety drugs. These effects resemble the symptoms of a panic attack. In addition, the possibility of paradoxical worsening of anxiety during the initial treatment of Panic disorder and its use for long term treatment are well established [6] . Therefore, the therapeutic use of Citalopram for treatment of Panic disorder is strongly in Psycho-agonistic mode (covers all three criteria). But when the Citalopram is used for the treatment of depression, however, its therapeutic use is still in Psycho-agonistic mode but less strongly. BNF has reported both ''suicidality, impaired concentration, sexual dysfunction and insomnia,.." (which resembles the symptoms of a depressive episode) and hypomania/mania which is opposite of depression. The possibility of paradoxical worsening of suicidality and anxiety in the initial treatment and suitability of using the medication for long-term treatment are well known [6] . Therefore it covers only two criteria from the Psychoagonistic mode. In situations where the information on the psychoactive effects of a drug and their clinical responses listed in the BNF were inconclusive, we used the Maudsley prescription guides [8] and other medical literature to guide decision making [9] [10] [11] .
Empirical data 85 psychotropic drugs were cross-matched to their BNF listed indications resulting in the identification of 105 'therapeutic uses'. It was possible to place all these therapeutic uses on a continuum between two Psycho-antagonistic or Psychoagonistic modes as defined above (Fig. 2 , Table 2 ).
Most therapeutic uses (97 out of 105 or 91%) can be allocated with reasonable confidence (meeting two or more criteria) into either Psycho-agonistic or Psycho-antagonistic mode. Only the therapeutic use of Lithium for bipolar affective disorder could not be allocated to any mode and considered as borderline. (Table 2) .
The other finding to emerge was that some individual drugs can be used in both Psycho-antagonistic and Psycho-agonistic modes -depending on their side-effect profile and different treatment indications. It was noted that the likely therapeutic responses shifted to that which was characteristic of the therapeutic mode of use. For example Olanzapine is used for the long term treatment of schizophrenia which is aligned with a Psycho-agonistic use of drug ( Table 2 ). Gradual 'symptom reduction' without developing tolerance and possibility of initial worsening of some symptoms (Akathisia) are aligned with therapeutic responses to Psycho-agonistic mode as well. However, when the sedative effect of Olanzapine is used to treat severe agitation in a patient with acute psychosis (rapid tranquilisation), it is used in a Psycho-antagonistic mode. Here the therapeutic responses are quick and emergence of tolerance (with requirement for increased drug doses) with longer term use [6, 8] have been reported ( Table 2 ).
Discussion
The current classification of the way psychotropic drugs are used within the BNF [6] is by action of a drug on an ''illness" i.e. antipsychotics, antidepressants etc. However, due to developments in our understanding of the drug's structure and/or receptor mechanisms there are subcategories within classes (e.g. tricyclics and SSRIs within the antidepressant class). Furthermore, it has become clear that drugs licensed for the treatment of specific illnesses are helpful in treating other illnesses (e.g. Venlafaxine for depression and anxiety disorders; Quetiapine for psychosis and bipolar depression) though with different recommended doses. This paper is the first (as far as we are aware) to draw attention to the relationship between the 'Psychoactive properties of a drug' and the 'Symptoms of illness' for which it is an indicated treatment and to use that relationship to conceptualise the ''therapeutic uses" of psychotropic drugs in a different way. Accommodating this conceptual shift is perhaps the main challenge as it requires us as psychiatrists to reflect and think more critically on our prescribing decisions and patients' responses to them, pending more research on the pathophysiology of psychiatric disorders. This requires, within an exploratory (or extended thought experiment) context, being mindful of alternative models and their potential significance both explicit and hidden, to prescribing decisions. The more explicit model is disease centred. The focus is on the ''target" response to the drugs only and that ''non-target" effects are understood as secondary by-products and unwanted generally. This concept is underlined by the language used to describe these other effects i.e. as ''side effects". An alternative concept considers all the drug effects as primary. These effects may be useful (therapeutic) or troublesome (side-effects) depending on the symptoms of illness they are used to treat. In this paper the focus is on considering the ill and healthy person's response to psychotropic drugs. Ironically, clinical practice can be seen as pragmatic in that prescribing decisions tend to use elements of both approaches -selecting agents with a side-effect profile that treat specific symptoms as well as targeting the underlying pathophysiology of the illness. For example Mirtazapine for treatment of a patient with depression who has marked insomnia. The prescriber's rationale for choosing an ''Anti-depressant" is likely to refer to the ''Diseasecentred" model or known receptor profile of the prescribed agent. However, the decision about which anti-depressant is likely here to be on the secondary by-product of sedation/ drowsiness of the drug (side effect). This is entirely appropriate and effective. However, are there any clinical advantages to making the hidden aspects of these decisions more explicit? More specifically, does a more explicit focus on a therapeutic use and response paradigm confer any potential clinical benefits?
To answer these questions, it is important to acknowledge the limitations of our study in advance. In terms of methodology, the main limitation was using the BNF side-effect profile of drugs as a proxy measure of their effects in healthy subjects. Given the constraints of conducting studies in healthy subjects, this approach may be acceptable as part of an exploratory approach. However, this means that currently the paradigm may not be able to explain all the reported paradoxical behaviours of psychotropic drugs for the same reason. The psychogenic properties of drugs are largely predetermined and therefore predictable. However we can only observe their interaction with the illness through the window of a human body which may respond uniquely either to the illness and/or the drug itself, as noted by the ''endophenotype" theory [12] . Proper ''fit for purpose" studies with large numbers of healthy subjects are needed therefore to address these issues (although they cannot be totally eliminated). And last but not least, we have refrained from including the off-license and add-on use of psychotropic drugs to avoid further complexity of interpretation. Whilst acknowledging these limitations, we have shown that:
-Firstly it is possible to identify therapeutic uses of psychotropic agents based on the BNF descriptors and to allocate almost all of them (except lithium for bipolar affective disorder) with a reasonable confidence (two or more criteria met) along a continuum between Psycho-antagonistic and Psycho-agonistic modes. The categorisation is clearly different to that of the BNF. -Secondly each group predicts likely characteristic therapeutic responses. The Psycho-antagonistic mode of use was associated with likely earlier symptom improvement but with gradual loss of effect after rather a short period. In contrast the Psycho-agonistic mode of use was associated with a delay to symptom reduction (and with possible initial worsening of symptoms) but with sustained clinical improvement. We have conceptualised the clinical responses to drugs when they are used in Psycho-agonistic or Psycho-antagonistic mode in Figs. 3 and 4 .
The clinical utility of this approach lies in these likely therapeutic responses. For example consider these two common clinical scenarios after initiating Risperidone 0.5 mg once a day for challenging behaviour of a patient with severe intellectual disability. We have chosen a person with severe intellectual disability to minimise the placebo effect.
Scenario one: The carers reported a significant improvement in the patient's sleep, mood and challenging behaviour after the first dose of Risperidone. These changes gradually reverted to the initial clinical presentation after 2-3 weeks.
Scenario two: The carers reported a gradual partial improvement in the patient's sleep pattern as well as in the intensity and frequency of challenging behaviours during the first 4-5 weeks after drug initiation. These changes have been maintained.
What should one decide about the Risperidone in each scenario? Current psychopathology and literature remain largely silent about distinguishing such subtle differences in clinical responses and leave the decision to the clinical judgement of Figure 3 Psycho-antagonistic use of drugs. the practitioner. Therefore, there might be an inconsistency in recommendations made by practitioners here. But let's see if our paradigm can be used as a complementary to other models and guidelines to fill in such gaps.
Given the clinical responses, we can clearly recognise a Psycho-antagonistic mode of therapeutic use of Risperidone in the first scenario and a psych-agonistic mode in the second. In the former, most probably, the sedative effect of Risperidone has ameliorated the patient's symptoms quickly but tolerance to this effect has gradually developed. Therefore, increasing the dose of Risperidone is unlikely to result in a sustained clinical improvement. In contrast, in the latter scenario, the clinical response is aligned with a psych-agonistic mode of the drugs' therapeutic use and therefore, continuing or increasing the dose is likely to result in sustained clinical improvement. Of course, the validity of such clinical predictions needs to be verified through robust clinical studies and trials.
In addition, grouping psychotropic drugs based on their therapeutic uses would make it easier for clinicians to predict and explain to patients their possible early response to the drug prescribed, the time to onset of the desired clinical benefits and the consequences of sustained use. The paradigm would raise the awareness of clinicians and patients of the possibility of initial worsening of symptoms and how to manage them -i.e. by reducing the dose. The management of initial worsening of Panic disorder (when treated with Citalopram) is a good example [6] . However in our opinion, the extent of current awareness about the likelihood and significance of initial ''paradoxical" symptom development is far less than what our paradigm indicates to be appropriate. Our study shows that 'initial worsening' is a potential feature of about 74% of therapeutic uses with a preponderance of enduring illness (depression and schizophrenia) indications. When translated to clinical practice, this awareness should influence prescribing decisions towards the 'lower doses' so as to minimise these risks and to assure a less distressing and more successful patient outcome. This is similar, but conceptually different to, recommendations that ''less is more" derived from several other ''disease centred" studies recommending smaller doses of psychotropic medication (e.g. Haloperidol and Risperidone) for better clinical results [13] [14] [15] [16] .
Whilst these advantages (and potential benefits) seem selfevident, clearly further clinical studies are needed to confirm the validity of these findings and explore the full extent of their clinical implications in psychiatry and perhaps in other branches of medicine. In addition, a new line of research would be on defining the psychoactive effect of psychotropic drugs on healthy subjects as identified by Dr. Moncriff [4] to avoid any interaction with the patient's symptoms.
Overview box:
What do we already know about the subject?
The mechanism of action of psychotropic drugs are explained by two approaches. The dominant ''Diseasecentred" view emphasises the biochemical imbalance caused by 'illnesses'. In contrast the ''Drug-centred" view emphasises the psychoactive properties of these drugs and their ability to induce an 'altered-state' of mind.
What does your proposed theory add to the current knowledge available, and what benefits does it have?
The paradigm highlights the possibility of initial worsening in majority of therapeutic uses of psychotropic drugs and importance of using lower doses in psychiatry. The paradigm complements current guidelines for making decision in different clinical scenarios.
Among numerous available studies, what special further study is proposed for testing the idea?
Whilst these advantages (and potential benefits) seem self-evident, clearly further properly designed (fit for purpose) clinical studies are needed to confirm the validity of these findings and explore the full extent of their clinical implications in psychiatry and perhaps in other branches of medicine. 
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